| scholarly article | Q13442814 |
| P50 | author | W. Martin Kast | Q78138546 |
| Ferry Ossendorp | Q90913429 | ||
| Rene E Toes | Q42494390 | ||
| P2093 | author name string | C. J. Melief | |
| R. Offringa | |||
| J. H. de Jong | |||
| M. E. Ressing | |||
| R. M. Brandt | |||
| P2860 | cites work | Cancer Research | Q326097 |
| Human tumor antigens recognized by T lymphocytes | Q24678508 | ||
| Cancer surveys | Q27710283 | ||
| Induction of anti-self-immunity to cure cancer | Q44641849 | ||
| Immunization against polyoma tumors with synthetic peptides derived from the sequences of middle- and large-T antigens | Q44753148 | ||
| A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. | Q45769906 | ||
| Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein | Q45789932 | ||
| Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells | Q46578425 | ||
| Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes | Q52112651 | ||
| Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. | Q54212663 | ||
| Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules | Q55042699 | ||
| Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. | Q55061347 | ||
| Viruses in human cancers | Q56486194 | ||
| Cellular immunity against human papillomavirus associated cervical cancer | Q56795682 | ||
| HLA antigens and cervical carcinoma | Q59074954 | ||
| Loss of MHC class-I expression in cervical carcinomas | Q68487810 | ||
| Role of cell-mediated immunity in spontaneous regression of plane warts | Q69831897 | ||
| Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice | Q70911259 | ||
| Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity | Q71563753 | ||
| Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 | Q71628036 | ||
| Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides | Q71802858 | ||
| The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer | Q71803276 | ||
| Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 | Q72052802 | ||
| Biological-clinical significance of selective loss of HLA-class-I allelic product expression in squamous-cell carcinoma of the uterine cervix | Q72464039 | ||
| Comparison of human leukocyte antigen DR-DQ disease associations found with cervical dysplasia and invasive cervical carcinoma | Q72558415 | ||
| Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes | Q72564569 | ||
| Papillomavirus Report | Q96327993 | ||
| Sequence analysis of peptides bound to MHC class II molecules | Q28303686 | ||
| Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. | Q30463850 | ||
| Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans | Q34195888 | ||
| Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens | Q34291693 | ||
| HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity | Q34339800 | ||
| Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. | Q34350288 | ||
| Tumor eradication by adoptive transfer of cytotoxic T lymphocytes | Q35867618 | ||
| Cellular studies on antigen presentation by class II MHC molecules | Q36166726 | ||
| Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles | Q36361966 | ||
| A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target | Q36362243 | ||
| Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. | Q36362670 | ||
| Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment | Q36364315 | ||
| T cell priming versus T cell tolerance induced by synthetic peptides | Q36365135 | ||
| Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes | Q36365159 | ||
| Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity | Q36366051 | ||
| Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines | Q36366108 | ||
| Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo | Q36366124 | ||
| Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines | Q36366405 | ||
| Human papillomaviruses in the pathogenesis of anogenital cancer | Q36413260 | ||
| Latent papillomavirus and recurring genital warts | Q36423789 | ||
| Naturally-occurring peptide antigens derived from the MHC class-I-restricted processing pathway | Q36713254 | ||
| Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells | Q37185460 | ||
| Structure, function, and diversity of class I major histocompatibility complex molecules | Q37820909 | ||
| Antigen recognition by class I-restricted T lymphocytes | Q38201551 | ||
| Paracrine cytokine adjuvants in cancer immunotherapy | Q38574486 | ||
| T Cell Subsets and the Recognition of MHC Class | Q40115713 | ||
| T‐Cell Immunotherapy of Tumors by Adoptive Transfer of Cytotoxic T Lymphocytes and by Vaccination with Minimal Essential Epitopes | Q40433282 | ||
| Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes | Q40433302 | ||
| Immunity to Oncogenic Proteins | Q40433308 | ||
| Antigen presentation to cytotoxic T lymphocytes in vivo. | Q40468618 | ||
| Alteration of signal transduction in T cells from cancer patients | Q40481505 | ||
| New strategies for enhancing the immunogenicity of tumors | Q40492275 | ||
| Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides | Q40553833 | ||
| Viral immunopathology of human tumors | Q40618658 | ||
| Tumor antigens recognized by T lymphocytes | Q40661131 | ||
| Cellular immunity against DNA tumour viruses: possibilities for peptide-based vaccines and immune escape. | Q40949075 | ||
| Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses | Q41234424 | ||
| Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors | Q41304280 | ||
| Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells | Q41532466 | ||
| Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide | Q41654974 | ||
| Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses | Q41655828 | ||
| Peptide-induced conformational change of the class I heavy chain | Q41683551 | ||
| Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex | Q42941471 | ||
| Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein | Q42941680 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| active immunotherapy | Q4677560 | ||
| P304 | page(s) | 241-251 | |
| P577 | publication date | 1996-11-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Immunotechnology : an international journal of immunological engineering | Q27714200 |
| P1476 | title | Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity | |
| P478 | volume | 2 |
| Q36550902 | Human papillomaviruses and cervical cancer |
| Q34182039 | Innovations and strategies for the development of anticancer vaccines |
| Q74556977 | Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein |
| Q33588526 | Prospects for the therapeutic use of anticancer vaccines |
| Q36285594 | Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer |
| Q37329072 | The influence of human papillomavirus type and HIV status on the lymphomononuclear cell profile in patients with cervical intraepithelial lesions of different severity |
Search more.